| Abstract [eng] |
Fallopian tube cancer is a rare malignancy, accounting for 1-2% of all gynecological malignancies. It is estimated that the incidence of fallopian tube cancer is approximately 0.41 cases per 100,000 population per year. The incidence of borderline tumors of the fallopian tube is even rarer, with only a few cases described in the scientific literature. Due to the rarity of this tumor type, comprehensive epidemiological data remain limited. The etiology of fallopian tube tumors is not yet fully understood. Demographic risk factors associated with the disease include patient age and a family history of fallopian tube or ovarian cancer. Histologically, these tumors resemble borderline serous ovarian tumors. Architecturally, they exhibit papillary structures of varying sizes and widths, forming cystic spaces lined with a pseudostratified epithelium. Cytologically, the cells are cuboidal or columnar in shape, often ciliated. Atypia is mild to moderate, characterized by cellular enlargement, coarse chromatin, small nucleoli, and minimal mitotic activity. According to case reports in the literature, the most common presenting symptom is lower abdominal or pelvic pain. Borderline serous tumors of the fallopian tube are typically diagnosed at a very early stage. The primary diagnostic methods include ultrasonography, magnetic resonance imaging (MRI), and blood tests; however, the definitive diagnosis is established histologically after surgical excision of the tumor. As these tumors are generally unilateral and non-invasive, the preferred surgical treatment for reproductive-age women desiring fertility preservation is ipsilateral salpingectomy, in which only the affected fallopian tube is removed. In older patients or those who do not wish to preserve fertility, bilateral salpingo-oophorectomy with total hysterectomy is recommended, involving the removal of both fallopian tubes, ovaries, and the uterus. Following surgical treatment, patients require regular follow-up for potential recurrence. Thesurveillance planincludesperiodic gynecological examinations, repeat imaging studies (ultrasonography, MRI), and measurement of the CA-125 tumor marker every six months and whole body (chest, abdomen and pelvis) computed tomography scan every 12 months (according to low-risk tumor follow-up recommendations). This scientific work presents a case of a reproductive-age female patient who was diagnosed with an ovarian cyst during a gynecological examination. During a surgical operation, a 3 cm cystic lesion was identified in the projection of the right fallopian tube. The patient underwent laparoscopic removal of a paratubal cyst of the right fallopian tube. The final pathological diagnosis confirmed a borderline serous tumor of the paratubal tissue. The patient is currently under clinical surveillance for potential recurrence. |
